Friday, July 10, 2026

pharma · Colitis, Ulcerative · Multiple Myeloma

Janssen Cilag International

Janssen-Cilag Farmaceutica Ltda is a pharma organization headquartered in São Paulo, EU. Primary therapeutic focus areas include Colitis, Ulcerative, Multiple Myeloma, Diabetes Mellitus, Type 2, Depressive Disorder, Majo

São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
46
Drugs
37
Patents
0
Clinical program

Apalutamide

Phase 2 · small molecule · Salivary Gland Neoplasms

Apalutamide for Salivary Gland Neoplasms is a Phase 2 program (small_molecule) at Janssen Cilag International NV with 1 ClinicalTrials.gov record(s).

Internal code CR108758

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Janssen Cilag International NV
Phase
Phase 2
Modality
small_molecule
Indication
Salivary Gland Neoplasms
Status
active
Trials
1